What it is:A chronic autoimmune disease where the immune system attacks the synovium, the thin lining inside joints. It's systemic, not just a joint problem: it can hit the lungs, eyes, heart, and bone marrow too. It's about three times more common in women, and it shortens life expectancy if left uncontrolled.
The core problem:An unclear trigger, probably infectious, sets off a cascade where T cells activate B cells to make autoantibodies. Those antibodies and the cytokines that come with them (TNF-α, IL-6, IL-1) build an angry, overgrown synovium called a pannusthat physically eats into cartilage and bone. Left alone, this is a one-way street toward deformity.
What you do about it:Start a conventional DMARD, almost always methotrexate, the moment the diagnosis is made, regardless of how mild it looks. Don't wait for damage to appear on an X-ray. Escalate fast if disease activity doesn't drop.
RA management runs on a single organizing idea: "treat to target."You pick a target (remission, or low disease activity if remission isn't realistic), measure it at every visit with a validated tool, and change therapy every time you're not hitting it. It's the same philosophy as titrating a blood pressure medication to a number, except the number here is a joint count and a lab value, and the stakes are irreversible bone erosion instead of a stroke.
RA needs three ingredients: genetic susceptibility, some nongenetic contributor, and a triggering event, most likely an infection nobody ever identifies. Once triggered, the immune system stops calling off the attack.
Antigen-presenting cells hand off an antigen to T cells. Activated T cells recruit B cells, and those B cells start manufacturing autoantibodies that clump into immune complexes and deposit throughout the body. Two of those antibodies matter clinically: rheumatoid factor (RF), which targets a patient's own IgG, and anti-citrullinated protein antibodies (ACPA / anti-CCP), which target citrullinated proteins. The same B cells also pump out TNF-αand a family of interleukins, which switch on adhesion molecules on blood vessel walls. That pulls in more T cells, drives cell migration into the joint, and kicks off matrix remodeling.
Every major drug class targets one node in this exact chain. Methotrexate, leflunomide, sulfasalazine, hydroxychloroquinebroadly dampen immune cell proliferation and inflammatory signaling. TNF inhibitorsneutralize TNF-α directly. IL-6 antagonists(tocilizumab, sarilumab) and IL-1 antagonist(anakinra) block specific cytokines from that same cascade. Abataceptstops T cells from ever getting activated in the first place by blocking the CD80/CD86-CD28 costimulation step. Rituximabdeletes the B cells making the antibodies. JAK inhibitorsblock the intracellular signaling that cytokines use once they've docked on their receptor. None of these regrow cartilage. All of them just stop feeding the fire.
Lymphocytes, macrophages, and mononuclear cells pour into the synovium and synovial cavity, and the synovium thickens and grows new blood vessels (angiogenesis, driven by IL-8, prostaglandins, VEGF, and macrophage angiogenic factor). This inflamed, fibrotic overgrowth is the pannus, and it physically invades cartilage and bone. Locally, cytokines push chondrocytes to break down matrix faster than they can rebuild it, and in bone they drive expression of RANKL, which switches on osteoclasts and eats away bone matrix. Meanwhile overexpression of the tumor suppressor p53 blocks normal DNA repair and apoptosis, which both drives more ACPA production and lets damaged synoviocytes keep proliferating instead of dying off on schedule.
RF titer correlates with severity, but ACPA is the one that predicts an aggressive courseand can show up before symptoms do. A seropositive patient (RF+ and/or ACPA+) with high titers is exactly who you escalate therapy in fastest, because the biology says the pannus is going to move quickly.
Chronic inflammation doesn't stay in the joint. It spreads to vascular endothelium and visceral, cutaneous, and pleural tissue, which is the mechanistic root of the extra-articular disease you'll see later: vasculitis, pulmonary fibrosis, anemia of chronic disease, and renal amyloidosis in longstanding, poorly controlled disease.
Onset is usually a slow burn, not a sudden flare. Over weeks to months patients develop nonspecific fatigue, weakness, low-grade fever, and appetite loss, with joint pain and stiffness often showing up before you can see or feel actual synovitis.
| Category | Findings |
|---|---|
| Joint pattern | Symmetric, small joints first: hands, wrists, feet, ankles. Can spread to elbows, knees, shoulders, hips, cervical spine, TMJ |
| Morning stiffness | Classically >30 minutes, sometimes lasting all day |
| Exam findings | Soft, spongy, warm, sometimes erythematous swelling (this is synovitis, not bony hypertrophy like OA) |
| Late deformity (untreated) | Bony erosions and subluxation of wrists, MCPs, PIPs: swan neck deformity, boutonnière deformity, ulnar deviation |
| Extra-articular | Rheumatoid nodules, interstitial lung disease, pleural effusions, vasculitis, ocular disease, pericarditis, cardiac conduction abnormalities, bone marrow suppression, lymphadenopathy |
RA morning stiffness lasts >30 minutes and often improves as the day goes on. OA morning stiffness is <30 minutes and resolves quickly with movement.RA joints are warm, boggy, and symmetric. OA joints are bony-hard (think Heberden's and Bouchard's nodes), asymmetric, and worsen with use rather than easing with it. If a question describes bilateral, symmetric hand and wrist swelling with an hour of morning stiffness, that's RA language, not OA language.
Diagnosis is clinical, built on history and exam, then confirmed with serology, inflammatory markers, and sometimes imaging. There's no single confirmatory test; RF and ACPA can both be negative in a real RA patient (seronegative RA), so a negative panel doesn't rule it out if the clinical picture is loud enough.
| Test | What it tells you |
|---|---|
| Rheumatoid factor (RF) | Positive in 70–80% of RA. Higher titers track with more severe disease. Not specific to RA, can be positive in other autoimmune and even some infectious conditions |
| ACPA / anti-CCP | More specific for RA than RF, can appear very early, often before symptoms. Predicts a more aggressive, erosive disease course |
| ANA | Positive in about 25% of RA patients; nonspecific |
| ESR / CRP | Elevated, confirms a nonspecific inflammatory process is active; useful for tracking response over time |
| CBC | Normocytic anemia of chronic disease is common; thrombocytosis or thrombocytopenia and leukopenia can also occur |
| Synovial fluid aspirate | High WBC count, but no crystals and no organisms, which is how you rule out gout and septic arthritis |
Early X-rays show soft tissue swelling and periarticular osteoporosis, findings that are easy to miss or dismiss. As disease progresses, you start seeing joint space narrowing, bony erosions, and the subluxations and deviations that define late, undertreated RA.
The 2010 ACR/EULAR classification criteria exist specifically to catch RA early, before erosive damage shows up, because that's the window where treatment changes the trajectory. A patient with synovitis in at least one joint (and no better explanation for it) is scored across joint involvement, serology, acute phase reactants, and symptom duration, out of a possible 10 points. A combined score ≥6classifies as definite RA. The whole point of this tool is to lower the bar for starting a DMARD, not to make you wait for radiographic proof.
Goal of therapy:remission, or if that's not realistic, low disease activity ("treat to target"). Underneath that: control inflammation and symptoms, keep the patient functional for daily activities, slow structural joint damage, and delay disability. Notice that "feeling better" is only part of the goal; the imaging and lab targets exist because joint destruction can be silent until it isn't.
Start a conventional DMARD immediately at diagnosis, regardless of how mild disease looks. Methotrexate preferred unless contraindicated.
Escalate to double/triple conventional DMARD combo, or a biologic (mono or with a conventional DMARD).
Start with monotherapy regardless of activity level. If mod-high after an adequate trial, escalate the same way: combo conventional, biologic, or JAK.
On TNFi monotherapy, mod-high activity: add 1-2 conventional DMARDs. Still uncontrolled: switch to a non-TNF biologic (preferred over JAK at this step). Failed two different TNFi's: non-TNF biologic. Failed multiple TNFi's and non-TNF isn't an option: JAK inhibitor.
NSAIDs and glucocorticoids never substitute for a DMARD.A patient "doing fine" on ibuprofen and low-dose prednisone with active synovitis is still accumulating joint damage, because neither drug slows disease progression. Dual biologic therapy is always wrong, tested constantly, because the infection risk stacks without a matching efficacy gain. And a glucocorticoid can be layered on top of any regimenfor a flare or inadequate control, but only at the lowest dose for the shortest time, it's an add-on, never the backbone.
These are first-line for a reason: they're the cheapest, best-studied, and (for methotrexate especially) fastest to access. Methotrexate is preferred across almost every step of the algorithm unless a contraindication rules it out.
Inhibits dihydrofolate reductase, which blocks DNA synthesis, repair, and cell replication broadly across rapidly dividing immune cells. Clinical benefit takes 3-6 weeks, so don't expect same-visit improvement.
Oral doses above 15 mg weeklymay stop adding benefit because GI absorption saturates. Switching to SC or IM at that point raises bioavailability, often recovers lost efficacy, and tends to cause fewer GI side effects than oral dosing did.
Folic acid 1-5 mg/dayis standard co-therapy: it cuts down on GI and hepatic adverse effects without blunting methotrexate's efficacy. There's essentially no reason to withhold it.
Pregnancy and breastfeeding(teratogenic; contraception required, stop before attempting conception), chronic liver disease, immunodeficiency, and preexisting hematologic disorderslike leukopenia or thrombocytopenia. Renal impairment slows methotrexate clearance and may require dose reduction or discontinuation.
Blocks pyrimidine synthesis, which slows lymphocyte proliferation. Efficacy is comparable to methotrexate, and it works as monotherapy or combined with other DMARDs. An optional 100 mg/day loading dose for 3 days gets to steady state faster but raises toxicity risk, so most patients just start at maintenance dosing. If GI intolerance, alopecia, or other dose-related toxicity shows up, the dose can be dropped from 20 mg/day to 10 mg/day.
Teratogenic, avoid in pregnancy, nursing, or severe hepatic impairment. Because it has a very long half-life and enterohepatic recirculation, an accelerated washout (cholestyramine) is used if a patient needs it cleared quickly, e.g. before pregnancy.
Sulfasalazineworks as mono or combo therapy, with benefit usually by 4 weeks but sometimes taking up to 12. GI adverse effects are the main thing limiting its use. It crosses the placenta and appears in breast milk but can be used cautiously in pregnancy and nursing, which makes it a go-to when a woman needs a conventional DMARD and methotrexate/leflunomide are off the table.
Hydroxychloroquineis usually paired with another DMARD, though it can stand alone in mild disease. Benefit is delayed, often several weeks. Its standout feature: it doesn't carry infection risk or hepatic/renal/blood cell toxicity, so it's the one conventional DMARD that doesn't need frequent routine labs. GI upset responds to taking it with food or splitting the dose. It's safe to continue through pregnancy (no demonstrated increase in birth defects or ocular toxicity) and is excreted in breast milk, so caution is advised while nursing.
Periodic ophthalmologic examsto catch irreversible retinal toxicity: baseline within 5 years of starting, then annually if risk factors for retinal damage exist, or annually starting at year 5 if there are none.
Reserved for when conventional DMARDs aren't cutting it, both because they're considerably more expensive and because they carry a distinct set of immunosuppression risks. They're genetically engineered proteins (except the JAK inhibitors, which are small-molecule oral drugs) that each block a specific point in the inflammatory cascade.
Block TNF-α directly. Clinical benefit takes several weeks to start and up to 3 months for full effect, so don't judge failure too early. Choice among agents mostly comes down to cost, insurance coverage, and patient preference for route/frequency, since head-to-head efficacy differences are modest.
Avoid in NYHA class III/IV heart failure: new-onset and worsening HF has been reported with TNF inhibitors. Also carries increased serious infection risk, malignancy risk (lymphoma, skin cancers), and can trigger new-onset or worsen demyelinating disease like MS.
Because it's a chimeric (part-mouse) antibody, the body can raise antibodies against it. Oral methotrexate must be co-administeredfor as long as the patient stays on infliximab to blunt that immunogenicity, and premedication with an antihistamine, acetaminophen, and/or a glucocorticoid reduces infusion reactions. Infliximab plus methotrexate outperforms methotrexate alone in trials, which is a nice illustration of why combination therapy exists at all.
Abatacept (Orencia)is a costimulation modulator: it binds CD80/CD86 on antigen-presenting cells so they can't deliver the second signal T cells need through CD28, so T cells never fully activate. Used after conventional DMARD monotherapy fails, as a TNFi alternative, or after TNFi failure. SC or IV, weight-based IV dosing.
Sarilumab (Kevzara)and tocilizumab (Actemra)are IL-6 receptor antagonists, used after incomplete response to at least one DMARD. Tocilizumab is available SC or IV and notably induces CYP3A4, which is worth flagging in a patient on a narrow-therapeutic-index CYP3A4 substrate.
Rituximab (Rituxan)binds CD20 on B cells, wiping out circulating B cells for months at a time. Reserved for patients with an incomplete response to at least one TNF inhibitor, and it should be given with methotrexate for the best outcome. Dosed as two 1000 mg infusions two weeks apart, re-dosed roughly every 24 weeks based on symptom return rather than a fixed schedule, since B cell recovery is slow. Premedicate with IV methylprednisolone, acetaminophen, and an antihistamine to blunt infusion reactions.
Anakinra (Kineret)blocks the IL-1 receptor. It's the least effective biologic in this group, used infrequently, and isn't part of current ACR treatment recommendations, but it remains an option after DMARD failure and can be combined with non-TNF DMARDs.
Baricitinib, tofacitinib, and upadacitinib block Janus kinase signaling downstream of cytokine receptors, essentially cutting the intracellular relay that TNF, IL-6, and other cytokines use once they've bound their receptor. All three are oral.
Baricitinibis approved after inadequate response to at least one TNF inhibitor. Tofacitiniband upadacitinibare approved after inadequate response or intolerance to methotrexate, one step earlier in the algorithm.
JAK inhibitors should not be given with biologic agents: same additive infection/immunosuppression logic as combining two biologics.
DMARDs take weeks to months to kick in, so NSAIDs, glucocorticoids, and acetaminophen fill the symptom-control gap while waiting. Neither NSAIDs nor glucocorticoids slow structural disease, and glucocorticoids carry real long-term toxicity, which is exactly why both are framed as temporary, not foundational.
Block prostaglandin synthesis, a relatively small slice of the overall inflammatory cascade. They relieve pain and stiffness quickly (faster onset than any DMARD) but do not slow disease progression or prevent erosions/deformity, so they're never appropriate as RA monotherapy.
| Drug | Usual adult anti-inflammatory dose | Schedule |
|---|---|---|
| Ibuprofen | 1.2–3.2 g/day | 3–4x daily |
| Naproxen | 0.5–1 g/day | Twice daily (ER once daily) |
| Meloxicam | 7.5–15 mg/day | Once daily |
| Celecoxib | 200–400 mg/day | Once or twice daily |
| Indomethacin | 50–200 mg/day | 2–4x daily (ER once daily) |
| Diclofenac | 150–200 mg/day | 3–4x daily (ER twice daily) |
symptom relief onlyEvery NSAID here treats pain and stiffness. None of them touch the pannus.
Anti-inflammatory and immunosuppressive, and they do slow RA progression somewhat, but they're never monotherapy because long-term toxicity is too high a price. ACR defines short-termuse as under 3 months and low-doseas prednisone ≤10 mg/day (or equivalent), and both matter: keep the dose low and the course short whenever possible.
| Drug | Start | Usual range / maintenance |
|---|---|---|
| Conventional DMARDs | ||
| Methotrexate (oral, SC, or IM) | Oral 7.5 mg once weekly (or 2.5 mg q12h x3 doses weekly); SC/IM 7.5 mg weekly | 7.5–20 mg/week; add folic acid 1–5 mg/day |
| Leflunomide | 20 mg daily (or 100 mg daily x3 days loading) | 10–20 mg daily |
| Hydroxychloroquine | 200 mg BID or 400 mg daily | 200 mg BID or 400 mg daily |
| Sulfasalazine | 500 mg once–twice daily | 1000 mg BID (max 3000 mg/day) |
| TNF inhibitors | ||
| Adalimumab (Humira) | 40 mg SC q2 weeks (up to weekly if not on MTX) | |
| Certolizumab (Cimzia) | 400 mg SC at 0, 2, 4 weeks | 200 mg q2 weeks or 400 mg q4 weeks |
| Etanercept (Enbrel) | 50 mg SC once weekly, or 25 mg SC twice weekly | |
| Golimumab (Simponi) | 50 mg SC once monthly | |
| Infliximab (Remicade) | 3 mg/kg IV at 0, 2, 6 weeks, then q8 weeks | 3–10 mg/kg IV q4–8 weeks; give with methotrexate |
| Non-TNF biologics | ||
| Abatacept (Orencia) | IV by weight (500/750/1000 mg) at 0, 2, 4 wk, or IV load then SC 125 mg within 24h | IV q4 weeks by weight, or SC 125 mg weekly |
| Sarilumab (Kevzara) | 200 mg SC q2 weeks | |
| Tocilizumab (Actemra) | IV 4 mg/kg q4 weeks; SC 162 mg q2 weeks (<100 kg) or weekly (>100 kg) | IV 4–8 mg/kg q4 weeks (max 800 mg/infusion) |
| Rituximab (Rituxan) | 1000 mg IV x2 doses, 2 weeks apart | Repeat course q16–24 weeks based on symptom return; premedicate with IV methylprednisolone |
| Anakinra (Kineret) | 100 mg SC once daily | |
| JAK inhibitors | ||
| Baricitinib (Olumiant) | 2 mg daily (1 mg daily with strong OAT3 inhibitors, e.g. probenecid) | |
| Tofacitinib (Xeljanz) | IR 5 mg BID or ER 11 mg daily (5 mg daily if renal/hepatic impairment or CYP3A4/CYP2C19 inhibitor) | |
| Upadacitinib (Rinvoq) | 15 mg ER daily | |
All biologics and JAK inhibitors suppress the immune system, and every one of them shares the same pre-treatment checklist and the same core risks. Learn this once and it applies to essentially the whole class.
TB screening(tuberculin skin test or interferon-gamma release assay) to catch latent TB before it reactivates under immunosuppression, and hepatitis B screeningbecause these drugs can reactivate a dormant infection. Treat latent TB before or concurrent with starting therapy.
Baricitinib, tofacitinib, and upadacitinib all carry boxed warnings for serious infection, malignancy (including lymphoma), and thrombosis(PE, DVT). That thrombosis warning is the one that separates JAK inhibitors from the biologics on this list and is a favorite exam detail.
A biosimilar has been verified to have no clinically meaningful difference from its reference biologic, and costs less, which improves access. The friction points are practical: there's no firm regulatory guidance on switching a stable patient from originator to biosimilar mid-treatment, and some uncertainty remains about extrapolating an indication studied in the originator product onto the biosimilar.
| Situation | What changes |
|---|---|
| Pregnancy planning | Methotrexate and leflunomide are teratogenic, stop and use contraception before conceiving. Hydroxychloroquine and sulfasalazine can generally continue with caution |
| Nursing | Hydroxychloroquine and sulfasalazine can be used cautiously; hydroxychloroquine is excreted in breast milk |
| Renal impairment | Methotrexate clearance drops, may need dose reduction or discontinuation; sulfasalazine not recommended |
| Hepatic impairment | Leflunomide not recommended if ALT >3x ULN; sulfasalazine not recommended |
| NYHA III/IV heart failure | Avoid TNF inhibitors; new-onset/worsening HF has been reported |
| Nonadherent patients | IM depot glucocorticoid injections provide 2–6 weeks of coverage with a built-in physiologic taper |
Two separate monitoring tracks run in parallel: tracking whether the disease is responding, and tracking whether the drugs are causing harm.
| Parameter | When | Watching for |
|---|---|---|
| Joint exam | Every visit | Swollen/tender joint count, mobility, deformity |
| Validated activity score(CDAI, DAS28, PAS, RAPID-3, SDAI) | Every visit | Objective treat-to-target number to drive escalation decisions |
| ESR / CRP | Periodically | Trending inflammation |
| Hand/wrist/forefoot X-rays | Baseline, then q2 years if low activity/remission; more often if mod-high | Periarticular osteopenia, new erosions, joint space narrowing → prompts a therapy change |
| Drug | Baseline | Maintenance |
|---|---|---|
| Methotrexate, leflunomide, sulfasalazine | CBC diff, SCr, AST/ALT (+ hep B/C and TB screen for MTX) | CBC diff, SCr, AST/ALT q2–4 weeks x3 months after start/dose increase, then q8–12 weeks through 3–6 months, then q12 weeks after 6 months |
| Hydroxychloroquine | Ophtho exam within 5 years of starting | Annual ophtho exam if risk factors present, or annually starting at year 5 if not |
| NSAIDs | SCr, CBC q2–4 weeks after starting | Same, plus stool guaiac q6–12 months |
| Glucocorticoids | - | Glucose, CBC periodically; BP q3–6 months |
| Biologics / JAK inhibitors | TB screen, hep B screen, CBC diff (+ LFTs, lipids for IL-6/JAK agents) | CBC diff and LFTs q4–8 weeks then q3 months; signs/symptoms of infection and malignancy at every visit |